# XBI holdings: all 165 positions

> All 165 XBI holdings with weights, as of Oct 13, 2026. The top 3 are MRNA 2.46%, TWST 1.86% and NTRA 1.85%. Download the full list as a CSV.

Data as of Oct 13, 2026. Rebuilt every trading night.

XBI held 165 positions as of Oct 13, 2026. Moderna Inc is the largest at 2.46%; the top 10 are 17.7% of the fund.

Source: State Street (https://www.ssga.com/us/en/intermediary/library-content/products/fund-data/etfs/us/holdings-daily-us-en-xbi.xlsx).

| # | Holding | Ticker | Weight |
| --- | --- | --- | --- |
| 1 | Moderna Inc | MRNA | 2.46% |
| 2 | Twist Bioscience Corp | TWST | 1.86% |
| 3 | Natera Inc | NTRA | 1.85% |
| 4 | Iovance Biotherapeutics Inc | IOVA | 1.70% |
| 5 | AbbVie Inc | ABBV | 1.69% |
| 6 | Biogen Inc | BIIB | 1.68% |
| 7 | United Therapeutics Corp | UTHR | 1.66% |
| 8 | Amgen Inc | AMGN | 1.63% |
| 9 | Halozyme Therapeutics Inc | HALO | 1.57% |
| 10 | Exelixis Inc | EXEL | 1.57% |
| 11 | Gilead Sciences Inc | GILD | 1.57% |
| 12 | TG Therapeutics Inc | TGTX | 1.53% |
| 13 | Protagonist Therapeutics Inc | PTGX | 1.47% |
| 14 | Regeneron Pharmaceuticals Inc | REGN | 1.44% |
| 15 | Vertex Pharmaceuticals Inc | VRTX | 1.44% |
| 16 | GRAIL Inc | GRAL | 1.44% |
| 17 | Spyre Therapeutics Inc | SYRE | 1.43% |
| 18 | Krystal Biotech Inc | KRYS | 1.42% |
| 19 | CRISPR Therapeutics AG | CRSP | 1.42% |
| 20 | Revolution Medicines Inc | RVMD | 1.40% |
| 21 | Vaxcyte Inc | PCVX | 1.39% |
| 22 | PTC Therapeutics Inc | PTCT | 1.37% |
| 23 | Alkermes PLC | ALKS | 1.35% |
| 24 | Neurocrine Biosciences Inc | NBIX | 1.34% |
| 25 | Alnylam Pharmaceuticals Inc | ALNY | 1.34% |
| | SSI US Gov Money Market Class | | 0.06% |
| | US Dollar | | -0.00% |
| | Cash and other net assets | | −0.03% |

The largest 25 of 165 positions are shown. All of them: https://etfiq.com/funds/xbi/holdings/xbi-holdings.csv (CSV) or https://etfiq.com/data/books/xbi.json (JSON).

Fund page: https://etfiq.com/funds/xbi

Cite: ETFIQ, Holdings of XBI, data as of Oct 13, 2026. https://etfiq.com/funds/xbi/holdings/